vs

Side-by-side financial comparison of Caesarstone Ltd. (CSTE) and Oncology Institute, Inc. (TOI). Click either name above to swap in a different company.

Oncology Institute, Inc. is the larger business by last-quarter revenue ($142.0M vs $94.4M, roughly 1.5× Caesarstone Ltd.). Oncology Institute, Inc. runs the higher net margin — -5.3% vs -93.1%, a 87.8% gap on every dollar of revenue. Oncology Institute, Inc. produced more free cash flow last quarter ($2.2M vs $-47.1M). Over the past eight quarters, Oncology Institute, Inc.'s revenue compounded faster (22.5% CAGR vs -57.8%).

Caesarstone Ltd., is a publicly traded company that engages in the production and marketing of quartz, porcelain, mineral and advanced fusion surfaces used for kitchen countertops, vanity tops, flooring, wall cladding and general interior design. The company was founded in 1987 and is traded on the NASDAQ in New York (CSTE). Headquarters are located in Kibbutz Sdot Yam in Israel. Production facilities are in Israel and India with third party manufactured product sourced from factories in the ...

Oncology Institute, Inc. is a specialized healthcare enterprise focused on delivering patient-centric, evidence-based oncology care services, including advanced treatment regimens, clinical trial access, and supportive care programs. It primarily operates across the United States, serving patients with diverse cancer diagnoses and partnering with care teams to improve treatment outcomes.

CSTE vs TOI — Head-to-Head

Bigger by revenue
TOI
TOI
1.5× larger
TOI
$142.0M
$94.4M
CSTE
Higher net margin
TOI
TOI
87.8% more per $
TOI
-5.3%
-93.1%
CSTE
More free cash flow
TOI
TOI
$49.2M more FCF
TOI
$2.2M
$-47.1M
CSTE
Faster 2-yr revenue CAGR
TOI
TOI
Annualised
TOI
22.5%
-57.8%
CSTE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CSTE
CSTE
TOI
TOI
Revenue
$94.4M
$142.0M
Net Profit
$-87.9M
$-7.5M
Gross Margin
15.5%
Operating Margin
-87.2%
-4.9%
Net Margin
-93.1%
-5.3%
Revenue YoY
41.6%
Net Profit YoY
43.0%
EPS (diluted)
$-2.55
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CSTE
CSTE
TOI
TOI
Q4 25
$94.4M
$142.0M
Q3 25
$345.4M
$136.6M
Q2 25
$237.7M
$119.8M
Q1 25
$104.4M
Q4 24
$100.3M
Q3 24
$436.7M
$99.9M
Q2 24
$294.3M
$98.6M
Q1 24
$150.6M
$94.7M
Net Profit
CSTE
CSTE
TOI
TOI
Q4 25
$-87.9M
$-7.5M
Q3 25
$-18.5M
$-16.5M
Q2 25
$-14.3M
$-17.0M
Q1 25
$-19.6M
Q4 24
$-13.2M
Q3 24
$-57.4M
$-16.1M
Q2 24
$-56.6M
$-15.5M
Q1 24
$-3.9M
$-19.9M
Gross Margin
CSTE
CSTE
TOI
TOI
Q4 25
15.5%
Q3 25
22.5%
Q2 25
23.7%
Q1 25
Q4 24
Q3 24
15.7%
Q2 24
14.1%
Q1 24
19.7%
Operating Margin
CSTE
CSTE
TOI
TOI
Q4 25
-87.2%
-4.9%
Q3 25
-5.5%
-5.9%
Q2 25
-6.2%
-9.4%
Q1 25
-9.5%
Q4 24
-11.9%
Q3 24
-12.6%
-13.9%
Q2 24
-18.0%
-16.6%
Q1 24
-3.9%
-19.0%
Net Margin
CSTE
CSTE
TOI
TOI
Q4 25
-93.1%
-5.3%
Q3 25
-5.4%
-12.1%
Q2 25
-6.0%
-14.2%
Q1 25
-18.8%
Q4 24
-13.1%
Q3 24
-13.1%
-16.1%
Q2 24
-19.2%
-15.7%
Q1 24
-2.6%
-21.0%
EPS (diluted)
CSTE
CSTE
TOI
TOI
Q4 25
$-2.55
$-0.04
Q3 25
$-0.54
$-0.14
Q2 25
$-0.41
$-0.15
Q1 25
$-0.21
Q4 24
$-0.14
Q3 24
$-1.67
$-0.18
Q2 24
$-1.64
$-0.17
Q1 24
$-0.11
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CSTE
CSTE
TOI
TOI
Cash + ST InvestmentsLiquidity on hand
$58.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$139.2M
$-15.7M
Total Assets
$398.4M
$164.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CSTE
CSTE
TOI
TOI
Q4 25
$58.4M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$9.9M
Q1 24
$29.8M
Total Debt
CSTE
CSTE
TOI
TOI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$-12.6M
Stockholders' Equity
CSTE
CSTE
TOI
TOI
Q4 25
$139.2M
$-15.7M
Q3 25
$271.6M
$-12.3M
Q2 25
$271.6M
$-9.0M
Q1 25
$5.1M
Q4 24
$3.6M
Q3 24
$315.1M
$15.5M
Q2 24
$315.1M
$29.2M
Q1 24
$315.1M
$41.3M
Total Assets
CSTE
CSTE
TOI
TOI
Q4 25
$398.4M
$164.7M
Q3 25
$549.0M
$163.6M
Q2 25
$549.0M
$159.8M
Q1 25
$164.0M
Q4 24
$172.7M
Q3 24
$579.9M
$179.2M
Q2 24
$579.9M
$179.6M
Q1 24
$579.9M
$204.5M
Debt / Equity
CSTE
CSTE
TOI
TOI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CSTE
CSTE
TOI
TOI
Operating Cash FlowLast quarter
$-38.0M
$3.2M
Free Cash FlowOCF − Capex
$-47.1M
$2.2M
FCF MarginFCF / Revenue
-49.8%
1.5%
Capex IntensityCapex / Revenue
9.6%
0.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$38.6M
$-27.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CSTE
CSTE
TOI
TOI
Q4 25
$-38.0M
$3.2M
Q3 25
$35.0M
$-12.6M
Q2 25
$18.7M
$-10.2M
Q1 25
$-5.0M
Q4 24
$4.2M
Q3 24
$53.3M
$819.0K
Q2 24
$25.1M
$-15.7M
Q1 24
$7.9M
$-15.9M
Free Cash Flow
CSTE
CSTE
TOI
TOI
Q4 25
$-47.1M
$2.2M
Q3 25
$26.7M
$-13.2M
Q2 25
$14.3M
$-11.4M
Q1 25
$-5.3M
Q4 24
$2.4M
Q3 24
$44.6M
$417.0K
Q2 24
$20.7M
$-17.5M
Q1 24
$5.0M
$-16.5M
FCF Margin
CSTE
CSTE
TOI
TOI
Q4 25
-49.8%
1.5%
Q3 25
7.7%
-9.7%
Q2 25
6.0%
-9.5%
Q1 25
-5.1%
Q4 24
2.4%
Q3 24
10.2%
0.4%
Q2 24
7.0%
-17.7%
Q1 24
3.3%
-17.4%
Capex Intensity
CSTE
CSTE
TOI
TOI
Q4 25
9.6%
0.7%
Q3 25
2.4%
0.4%
Q2 25
1.8%
1.0%
Q1 25
0.3%
Q4 24
1.8%
Q3 24
2.0%
0.4%
Q2 24
1.5%
1.9%
Q1 24
1.9%
0.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CSTE
CSTE

America's$53.0M56%
USA$41.4M44%

TOI
TOI

Other$82.1M58%
Fee For Service$36.3M26%
Capitated Revenue$23.6M17%

Related Comparisons